Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

Boston (March 31, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP/WNT pathway inhibitor—today announced financial results for the year ended December 31, 2024, and provided a general business update. Thomas Jensen, Chief Executive Officer of Allarity Therapeutics, stated: "2024 was a transformational year for Allarity as we made significant progress in advancing sten ...